- Category
- Micro (2023-24)
- Udyam number
- UDYAM-UP-03-0029546

Riedeli Pharmaceuticals Private Limited
About Riedeli Pharmaceuticals Private Limited
Data last updated:
Riedeli Pharmaceuticals Private Limited is a private limited company based in Allahabad, Uttar Pradesh, India. It operates in the diversified business activities segment of the business services sector. It was incorporated on 18 June 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Kanpur, under CIN U74999UP2018PTC105445. Its GSTIN is 09AAJCR0083J1Z4 (Uttar Pradesh).
The company has an authorised share capital of ₹5 Lakh and a paid-up capital of ₹5 Lakh. It is led by directors Mohit Kumar Pandey and Pallavi Pandey.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Dandi Naini, Allahabad, Uttar Pradesh, India – 211008.
As per the financials filed for FY 2024, the company reported a revenue of ₹5.95 Lakh, a decline of 1% compared to the previous year. For the same year it recorded a net loss of ₹2,503 (net margin -0.4%) and EBITDA of ₹38,437 (EBITDA margin 6.5%). Revenue has declined at a compounded annual rate (CAGR) of 32% over three years.
As per MCA filings, the company has open charges of ₹6.5 Lakh on record.
Riedeli Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-UP-03-0029546).
Recognitions & Rankings of Riedeli Pharmaceuticals
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressDandi Naini, Allahabad, Uttar Pradesh, India – 211008
- IndustryBusiness Services, Miscellaneous Business Activities, Other Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Riedeli Pharmaceuticals Private Limited
The main business activity of Riedeli Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Riedeli Pharmaceuticals Private Limited FY 2024 filings available
Riedeli Pharmaceuticals Private Limited reported revenue of ₹5.95 Lakh (down 1% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR) of Riedeli Pharmaceuticals Private Limited
Revenue has declined at a compounded annual rate (CAGR) of 32% over three years, including a 1% fall in the latest year. EBITDA rose 153% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Riedeli Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹38,437 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | -₹2,503 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Riedeli Pharmaceuticals Private Limited
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 6.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | -0.4% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Riedeli Pharmaceuticals are in the company report.
Financial statements from FY 2019
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Riedeli Pharmaceuticals Private Limited
Riedeli Pharmaceuticals has 2 current directors and 1 former director. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mohit Kumar Pandey | Director | 18 Jun 2018 | 8 Years 4 Months | Current |
| Pallavi Pandey | Additional Director | 05 Aug 2019 | 7 Years 2 Months | Current |
Peer Comparison of Riedeli Pharmaceuticals Private Limited
Riedeli Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Innogent Pharmaceuticals Private Limited | ₹6.01 Lakh (FY 2025) | •••• | •••• | •••• | Navi Mumbai, Maharashtra, India | |
| Krishicon Pharmaceuticals Private Limited | ₹6 Lakh (FY 2025) | •••• | •••• | -43.0% | •••• | Thane, Maharashtra, India |
| Novarance Pharmaceuticals Private Limited | ₹6 Lakh (FY 2025) | •••• | •••• | 73.0% | •••• | Mirzapur, Uttar Pradesh, India |
| Felding Roth Pharmaceuticals Private Limited | ₹5.96 Lakh (FY 2025) | •••• | •••• | -13.0% | •••• | Lucknow, Uttar Pradesh, India |
| Zisel Pharmaceuticals Private Limited | ₹5.96 Lakh (FY 2020) | •••• | •••• | 5830.0% | •••• | Varanasi, Uttar Pradesh, India |
| Riedeli Pharmaceuticals Private Limited this company | ₹5.95 Lakh (FY 2024) | •••• | •••• | -1.0% | •••• | Allahabad, Uttar Pradesh, India |
| Prumed Pharmaceuticals Private Limited | ₹5.94 Lakh (FY 2025) | •••• | •••• | -49.0% | •••• | Saurbazar, Bihar, India |
| Denice Pharmaceuticals Private Limited | ₹5.92 Lakh (FY 2022) | •••• | •••• | 91.0% | •••• | Jabalpur, Madhya Pradesh, India |
| Microsys Pharmaceuticals Private Limited | ₹5.9 Lakh (FY 2022) | •••• | •••• | -9.0% | •••• | Hathras, Uttar Pradesh, India |
| Lucida Pharmaceuticals Private Limited | ₹5.9 Lakh (FY 2025) | •••• | •••• | -33.0% | •••• | Aurangabad, Maharashtra, India |
| Gour Pharmaceuticals Private Limited | ₹5.9 Lakh (FY 2022) | •••• | •••• | 51.0% | •••• | Sehore, Madhya Pradesh, India |
Peers are the five companies nearest above and the five nearest below Riedeli Pharmaceuticals by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Ownership and Shareholding of Riedeli Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Riedeli Pharmaceuticals Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Jun 2020 | Others | ₹6.5 Lakh | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Riedeli Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Riedeli Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Riedeli Pharmaceuticals Private Limited
Riedeli Pharmaceuticals Private Limited has 3 board changes on record since 2018: 2 appointments and 1 cessation. The latest: Pallavi Pandey was appointed as Additional Director on 05 Aug 2019.
Credit Ratings, Litigation & Regulatory Alerts for Riedeli Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Riedeli Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Riedeli Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Riedeli Pharmaceuticals Private Limited
Riedeli Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 09AAJCR0083J1Z4 | Uttar Pradesh | Active | 26 Apr 2019 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Riedeli Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Riedeli Pharmaceuticals Private Limited
Riedeli Pharmaceuticals is an active private limited company based in Allahabad, Uttar Pradesh, India. The company works in miscellaneous business activities, within the business services industry. It was incorporated on 18 June 2018 (8+ years old) and is registered under CIN U74999UP2018PTC105445.
Riedeli Pharmaceuticals reported revenue of ₹5.95 Lakh for FY 2024 (down 1% YoY).
Riedeli Pharmaceuticals has 2 current directors:
- Mohit Kumar Pandey - Director
- Pallavi Pandey - Additional Director
Riedeli Pharmaceuticals reported a net loss of ₹2,503 (net margin -0.4%) and EBITDA of ₹38,437 (EBITDA margin 6.5%) for FY 2024, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Riedeli Pharmaceuticals is -32% over three years. In the latest year (FY 2024) revenue fell 1%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Riedeli Pharmaceuticals is 09AAJCR0083J1Z4, registered in Uttar Pradesh.
The CIN (Corporate Identification Number) of Riedeli Pharmaceuticals is U74999UP2018PTC105445. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Riedeli Pharmaceuticals was incorporated on 18 June 2018, making it 8+ years old. It is registered with the Registrar of Companies, Kanpur.
The peers of Riedeli Pharmaceuticals by revenue are Innogent Pharmaceuticals Private Limited, Krishicon Pharmaceuticals Private Limited, Novarance Pharmaceuticals Private Limited, Felding Roth Pharmaceuticals Private Limited, Zisel Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Pallavi Pandey was appointed as Additional Director on 05 Aug 2019. Chandra Prakash ceased to be Director on 27 Jul 2019. Mohit Kumar Pandey was appointed as Director on 18 Jun 2018.
Yes, Riedeli Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-UP-03-0029546).